SCHEMBL5368735

SCHEMBL5368735

CC(C)(C)c1cc(C=O)cc(Cl)c1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 3/20 0.41
ALDH1A1 P00352 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CYP1A2 P05177 2/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5366582 0.90 MAOA (0.51) MAOAMAOBSMN1; SMN2KDM4ELMNA
SCHEMBL4293786 0.86 MAOA (0.55) MAOAMAOBSMN1; SMN2MEN1KMT2A
SCHEMBL5365873 0.84 MAOA (0.46) MAOAMAOBSMN1; SMN2KMT2ALMNA
SCHEMBL5369726 0.84 MAOA (0.46) MAOAMAOBKDM4ELMNAALDH1A1
SCHEMBL6781405 0.81 SMN1; SMN2 (0.51) MAOAMAOBSMN1; SMN2MEN1KMT2A
SCHEMBL30821655 0.81 SMN1; SMN2 (0.51) MAOAMAOBSMN1; SMN2MEN1KMT2A
SCHEMBL5367770 0.80 MAOA (0.42) MAOAMAOBMEN1KMT2AALDH1A1
SCHEMBL4839769 0.80 ALDH1A1 (0.58) MAOAMAOBSMN1; SMN2MEN1KMT2A
SCHEMBL1406410 0.79 MAOB (0.44) MAOAMAOBLMNANPC1HTT
SCHEMBL16055528 0.79 KMT2A (0.62) MAOAMAOBSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
US-6506763-B2 Useful in prevention and treatment of protein kinase related disorders such as cancer SUGEN, INC. 2003-01-14 US disclosed
US-6133305-A PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER SUGEN, INC. (US) 2000-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAOA 1231/4885MAOB 867/4885SMN1; SMN2 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.